Electra Therapeutics

Electra Therapeutics (Ticker: ETRA US) develops experimental medicines for immune-related diseases and cancer, with programs addressing specific immune cells involved in illness. Its treatments are designed to target and remove specific immune cells that contribute to disease, rather than broadly suppressing the immune system. ELA822 is in development for immune and inflammatory diseases involving T cells. Ipsoprubart is being tested in a late-stage Phase 2/3 clinical trial for secondary hemophagocytic lymphohistiocytosis, a condition involving excessive immune-system activation.

The scheduled listing date on Nasdaq was September 18, 2026. The offering comprises 23,330,000 shares at a confirmed price of $15.00 per share. At the confirmed offer price, the base offering represents $349.95 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $941.00 million.

Jefferies, TD Cowen, Evercore ISI and Cantor are managing the IPO.